These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11964319)

  • 1. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.
    Milella M; Estrov Z; Kornblau SM; Carter BZ; Konopleva M; Tari A; Schober WD; Harris D; Leysath CE; Lopez-Berestein G; Huang Z; Andreeff M
    Blood; 2002 May; 99(9):3461-4. PubMed ID: 11964319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
    Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S
    Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia.
    Milella M; Kornblau SM; Estrov Z; Carter BZ; Lapillonne H; Harris D; Konopleva M; Zhao S; Estey E; Andreeff M
    J Clin Invest; 2001 Sep; 108(6):851-9. PubMed ID: 11560954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.
    Yu C; Wang S; Dent P; Grant S
    Mol Pharmacol; 2001 Jul; 60(1):143-54. PubMed ID: 11408609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
    Hu Y; Bally M; Dragowska WH; Mayer L
    Mol Cancer Ther; 2003 Jul; 2(7):641-9. PubMed ID: 12883037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of the effects of the MEK inhibitor U0126 on apoptosis in acute leukemia.
    James JA; Smith MA; Court EL; Yip C; Ching Y; Willson C; Smith JG
    Hematol J; 2003; 4(6):427-32. PubMed ID: 14671615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
    Milella M; Konopleva M; Precupanu CM; Tabe Y; Ricciardi MR; Gregorj C; Collins SJ; Carter BZ; D'Angelo C; Petrucci MT; Foà R; Cognetti F; Tafuri A; Andreeff M
    Blood; 2007 Mar; 109(5):2121-9. PubMed ID: 17077328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.
    Zhang W; Ruvolo VR; Gao C; Zhou L; Bornmann W; Tsao T; Schober WD; Smith P; Guichard S; Konopleva M; Andreeff M
    Mol Cancer Ther; 2014 Jul; 13(7):1848-59. PubMed ID: 24739393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.
    Oliver L; Mahé B; Gréé R; Vallette FM; Juin P
    Leuk Res; 2007 Jun; 31(6):859-63. PubMed ID: 17224180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
    Verhaegen M; Bauer JA; Martín de la Vega C; Wang G; Wolter KG; Brenner JC; Nikolovska-Coleska Z; Bengtson A; Nair R; Elder JT; Van Brocklin M; Carey TE; Bradford CR; Wang S; Soengas MS
    Cancer Res; 2006 Dec; 66(23):11348-59. PubMed ID: 17145881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
    Wu J; Wong WW; Khosravi F; Minden MD; Penn LZ
    Cancer Res; 2004 Sep; 64(18):6461-8. PubMed ID: 15374955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
    Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death.
    Lickliter JD; Wood NJ; Johnson L; McHugh G; Tan J; Wood F; Cox J; Wickham NW
    Leukemia; 2003 Nov; 17(11):2074-80. PubMed ID: 12931228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
    Kojima K; Konopleva M; Samudio IJ; Ruvolo V; Andreeff M
    Cancer Res; 2007 Apr; 67(7):3210-9. PubMed ID: 17409429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor.
    An J; Chervin AS; Nie A; Ducoff HS; Huang Z
    Oncogene; 2007 Feb; 26(5):652-61. PubMed ID: 16909121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
    Hu Y; Dragowska WH; Wallis A; Duronio V; Mayer L
    Breast Cancer Res Treat; 2001 Nov; 70(1):11-20. PubMed ID: 11767000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
    Miranda MB; McGuire TF; Johnson DE
    Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.